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1. ABSTRACT 
Objectives.  To investigate primary success rates and long term follow-up of endovascular treatment 
of AngioSealTM–related limb ischemia. 
Background.  Current knowledge on optimal therapy of ischemic complications following application 
of AngioSealTM is limited. 
Methods.  A single-center prospectively maintained data base was retrospectively interrogated and 
AngioSealTM – related complications requiring endovascular treatment over an eight year time period 
were identified.   
Results.  Fifteen patients fulfilling the inclusion criteria were identified, resulting in an approximated 
incidence of 0.26% of all device implanted at our institution. In all cases, the complication was 
managed successfully in the absence of complications. 11 patients were treated with balloon 
angioplasty (PTA) and 4 with stent implantation because of suboptimal PTA results. Twelve patients 
were available for non-invasive vascular follow-up examination for a median time of 40 months 
postinterventionally. Only two patients needed a second intervention consisting of balloon angioplasty 
due to symptomatic restenosis. At final follow-up all patients were asymptomatic with no relevant 
restenosis.  
Conclusion.  Endovascular treatment for AngioSealTM–related limb ischemia with or without stent 
implantation results in an excellent immediate and long-term clinical and hemodynamic outcome.  
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2. INTRODUCTION 
Femoral artery closure devices are widely used after cardiac and peripheral vascular interventions with 
the intention to decrease post-procedure manual compression time as well as bleeding complications 
(1).  These devices have proven their efficacy in obtaining immediate haemostasis after sheath 
removal, allowing for early mobilization and hospital discharge, improving the patient’s comfort.  
However, the risk of access-site-related complications for most femoral artery closure devices remains 
similar compared with manual compression (2).  Device-related vascular injuries include 
pseudoaneurysm, arteriovenous fistula, hematoma, and femoral artery stenosis or thrombosis (2).  
The AngioSealTM femoral artery closure device is a bioabsorbable, sheath-delivered device, which 
seals the puncture defect with a small collagen plug (1,3).  Femoral artery stenosis and occlusions 
leading to severe limb ischemia or intermittent claudication following AngioSealTM deployment have 
been described (4-6). Although ischemic complications after implantation of AngioSealTM are rare, the 
resulting sequelae with intermittent claudication or severe limb ischemia are of clinical relevance.  The 
treatment of choice of these device-related complications remains unknown. The decision to 
conservative, endovascular or surgical management depends on the severity of symptoms and 
anatomical localization of the obstruction. Small uncontrolled series have reported on successful 
surgical therapy with desobliteration and thrombectomy (4-5,7-11).  Data on interventional therapy 
using percutaneous transluminal angioplasty (PTA) with or without stent implantation are limited to 
case reports and small series with a limited follow up period between three and six month (12-16).  To 
our knowledge, the moist comprehensive study was reported by Steinkamp et al. using excimer laser-
assisted recanalisation in 16 patients with clinical follow up at 6-month (15).   
In summary, current knowledge on optimal therapy of ischemic complications following application of 
AngioSealTM is limited, especially long term follow-up studies are currently lacking (Table I).   
The aim of this study was to investigate success rate and long-term results of symptomatic 
AngioSealTM- related complications treated by an endovascular approach and to ascertain long-term 
outcome by means of clinical, duplex ultrasound, and ankle-brachial-index (ABI) at follow-up.  
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3. MATERIALS AND METHODS 
Our single-center prospectively maintained data base was retrospectively interrogated for the time 
period between 2000 and 2007 for endovascular management of AngioSealTM–related complications.  
Only patients presenting with clinical symptoms such as rest pain or intermittent claudication were 
referred to the vascular clinic and had therefore been included in the analysis.  Ultrasound exams of all 
patients treated with AngioSealTM was not routinely done. Non-invasive vascular examination including 
pulse wave recordings and measurement of the ankle-brachial index (ABI) had been performed at 
baseline and one day, 3, 6 and 12 months after the procedure and annually thereafter. At baseline and 
when restenosis was suspected the degree of the obstruction was determined by color coded duplex 
sonography (CCDS).  Endovascular treatment was performed in the routine manner from a 
contralateral approach using a 4 to 6 Fr sheath inserted into the common femoral artery (CFA). After 
diagnostic angiography confirming the obstruction, a bolus of 5000 units of unfractionated heparin was 
injected intra-arterially.  The lesion was crossed with a 0.018 wire (Boston Scientific, Natik, MA, USA) 
and angioplasty was done with over-the-wire balloon catheters with a long inflation time up to three 
minutes (Figure I). In cases with insufficient angiographic results self-expandable nitinol stents 
(6/30mm – 9/30mm) had been implanted (Figure II). Successful angioplasty was defined by a final 
angiogram with residual stenosis of less than 50% since some regression of the obstruction by healing 
of the dissection was expected and stent placement therefore when ever possible avoided.  Post-
interventional therapy consisted of aspirin 100mg/day combined with clopidogrel 75mg/day for four 
weeks after stent implantation. In case of clinical relevant restenosis or reocclusion a second 
endovascular treatment was performed using the same technique. 
Clinical information were obtained from the prospective clinical data base and collected in an 
anonymized form. Descriptive data were expressed as median values and ranges. 
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4. RESULTS 
In the time period of eight years (2000 to 2007) 15 patients fulfilling the inclusion criteria were 
identified.  Over this period estimated 5800 closure devices of the type AngioSealTM were used at our 
hospital, resulting in an approximated incidence of device related complications of 0.26%.  
Patient’s characteristics are given in Table II.  Median age was 55 (45 – 82) years, gender was 
uniformly distributed (8 men/7 women).  Critical limb ischemia had occurred in five patients immediate 
after insertion of the AngioSealTM device, while all others presented with limiting claudication after 
placement of the device.  The CFA was affected in 10, the superficial femoral artery (SFA) in five 
patients. In six patients an occlusion and in nine a high grade stenosis of the vessel was diagnosed by 
CCDS and confirmed by angiography. In all patients crossing the lesion from the contralateral 
approach and balloon angioplasty (PTA) was possible without further complication as distal 
embolization or bleeding at the puncture site. In four patients stent implantation was necessary due to 
insufficient result after PTA. 
In two patients initially treated with plain angioplasty a second PTA without stent implantation was 
necessary due to a symptomatic restenosis of the common and proximal superficial femoral artery 
after 3 and 6 month, respectively. The final follow-up after 41 and 17 months of these two patients was 
unremarkable (Table II).  
Three patients died during follow up unrelated to critical limb ischemia.  The median follow-up time of 
the remaining 12 patients was 41 (4 – 79) months.  At final follow up all patients were asymptomatic 
and no relevant restenosis was detected by CCDS.  
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Table I:  
 
Reported therapy of lower limb ischemic complications after the use of AngioSealTM  
 
 
 
Author  
(Reference) 
Year 
 
Patients 
[n] 
Localisation Therapy Follow-up 
[month] 
Stein (14) 2000 1 CFA endovascular n.a. 
Goyen (12) 2000 5 CFA, PA endovascular 0 - 4 
Steinkamp (15) 2001 16 CFA, PFA, SFA endovascular 0 - 6 
Kirchhof (5) 2002 10 CFA, SFA surgery (most) 2 - 3 
Shaw (13) 2003 1 CFA endovascular 3 
Thalhammer (4) 2004 14 CFA, SFA, PFA, EIA, CIA surgery (most) n.a. 
Abando (11) 2004 1 CFA surgery n.a. 
Mukhopadhyay (17) 2005 1 n.a. conservative 0 
Biancari (9) 2006 3 CFA surgery 0 - 3 
Dregelid (8) 2006 4 CFA, SFA surgery 0 - 1 
Castelli (10) 2006 4 CFA, SFA surgery 1 - 12 
Lee (16) 2007 1 CFA endovascular 1 
Kadner (7) 2008 7 CFA surgery 1 - 12 
 
CFA: common femoral artery; PA: popliteal artery; SFA: superficial femoral artery; EIA: external iliac 
artery; CIA: common iliac artery; n.a.: not available 
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Table II:  
 
Patients’ characteristics 
 
 
 
Age 
[years] 
Sex 
[m/f] 
Symptoms Localisation Lesion Therapy Follow-up 
[month] 
Re-intervention 
78 f CLI SFA Occlusion Stent ┼ - 
46 m CLI CFA Occlusion Stent ┼ - 
81 f CLI CFA Occlusion Stent 29 - 
58 m Claudication CFA Occlusion Stent 42 - 
65 f Claudication CFA Stenosis PTA 29 - 
66 f Claudication CFA Stenosis PTA 45 - 
55 m CLI CFA Stenosis PTA 41 CFA stenosis 
69 m CLI SFA Stenosis PTA 41 - 
54 f Claudication CFA Stenosis PTA 40 - 
45 m Claudication SFA Stenosis PTA 58 - 
54 f Claudication CFA Stenosis PTA 4 - 
53 m Claudication SFA Occlusion PTA 17 SFA stenosis 
82 f Claudication CFA Occlusion PTA ┼ - 
54 m Claudication SFA Stenosis PTA 79 - 
51 m Claudication CFA Stenosis PTA 37 - 
 
m: male; f: females; CLI: critical limb ischemia; SFA: superficial femoral artery; CFA: common femoral 
artery; PTA: percutaneous transluminal angioplasty; ┼ dead during follow up. 
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A B
Figure 1: Angiogram of a 51 years old male patient with severe claudication of the right leg after AngioSealTM
implantation (A) The right common femoral artery shows a short circumscribed high grad stenosis, which was 
successfully treated with balloon angioplasty (B)
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A B C
Figure 2: The angiogramm confirmed a short occlusion of the non-calcified right common femoral artery after
AngioSealTM application in a 58 years old patient (A). Due to dissection flow was still limited after angioplasty (B) 
and therefore a nitinol stent had been implanted (C) 
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5. DISCUSSION 
This is the first report on long-term outcome of AngioSealTM–related vascular complications treated by 
an endovascular approach.  Consistent with the current knowledge ischemic complications after the 
use of closure devices are rare with an estimated incidence in our series of 0.26% (2,4). Our data 
support the currently published data that PTA with and without Stent implantation in lesions due to 
AngioSealTM is feasible and safe with good immediate results and excellent long-term outcome.  Sole 
angioplasty is the preferred strategy in this setting; however in complete CFA occlusions or suboptimal 
PTA results stent implantation may become necessary.  In our series, we did not find stent-related 
complications as kinking or intimal hyperplasia at follow up in the four patients treated.  Arterial closure 
devices are increasingly used after percutaneous endovascular procedures and an absolute increase 
in ischemic complications may be expected in the future (2).  Therefore, further data concerning the 
different therapeutic options and its outcome are needed. In cases with non-limiting claudication a 
conservative approach with “watchful waiting” is recommended since dissolving of the collagen plug 
may further reduce the obstruction (4,17).  However, depending on the lesion characteristics 
(dissection, flow turbulences) short time anticoagulation might be discussed to avoid embolization. At 
our institution all clinical relevant complications had been successfully treated by balloon angioplasty 
and in some cases with stent implantation. From our experience surgical removal of the device with 
reconstruction of the vessel should be avoided since excellent long-term results after endovascular 
therapy can be achieved. In severe limb ischemia, immediate restoration of blood flow is mandatory 
and especially after coronary interventions open vascular surgery is associated with higher morbidity 
than the endovascular approach (18). In addition, the majority of patients are treated with dual 
antiplatelet therapy and this can increase the bleeding complications following surgical revision. 
Additional non-life threatening but disturbing complication include lymphatic fistulas, infections and 
delayed wound healing. Furthermore, possible complications of surgery in the groin area as lymphatic 
fistulas, infections and delayed wound healing might occur.  Nevertheless, immediate and long term 
results after endarterectomy of the femoral bifurcation in case of heavily calcified lesions not related to 
AngioSealTM are excellent (18-19). It is important to realize that the immediate result after PTA has not 
to be perfect, since healing of the dissection and dissolving of the AngioSealTM plug will occur and 
regression of residual stenosis is common as we could document in our series by CCDS. 
Our data support the currently published data that PTA with and without stent implantation in lesions 
due to AngioSealTM is feasible and safe with good immediate results and excellent long-term outcome.  
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Sole angioplasty is the preferred strategy; however in complete occlusions with dissection stent 
implantation may become necessary.  In our series, we did not find stent-related complications as 
kinking or intimal hyperplasia during follow-up.  The incidence of restenosis up to five years was less 
than 20% due to the primarily non-atherosclerotic nature of the lesion.  
The main limitation of the study is the small number of patients.  Furthermore, no systematic 
ultrasound examinations after AngioSealTM implantation had been performed which may result in an 
underestimation of asymptomatic AngioSealTM-related lesions. Finally, the estimation of the incidence 
of device-related complication was based on the number of devices used. However, we cannot 
exclude that patients with lower limb ischemic complication related to AngioSealTM were not referred to 
our center for treatment despite the fact that the index endovascular procedure was performed at our 
institution. 
 
 
5. CONCLUSIONS 
Endovascular treatment with or without stent implantation for AngioSealTM–related limb ischemia can 
achieve excellent immediate and long-term clinical and hemodynamic outcome.  
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